Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

BAKER CAPITAL STRATEGIES

Get the free weekly BCS email.

Selected company filings and market updates, delivered by email. Your first report will follow soon.

  • Your weekly BCS reportMarket updates and links to filings you can explore.
  • THEMA at launchWe’ll send directions for setting up your filing alerts when THEMA officially opens.

One signup for the weekly email and your free THEMA Basic account at launch.

Already registered or a CSW member?Log in to THEMA →

At least 8 characters. This also creates your free THEMA account for launch.

You’re signing up for the weekly BCS email and THEMA launch/setup updates. Unsubscribe using the link in any email. Privacy policy · Terms

BCS

Current Report · Items 5.02, 5.03, 5.07, 9.01 · 8-K

Firefly Neuroscience, Inc.

AIFFNASDAQEQUITYCurrent

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security Holders

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 5, 2026, at the 2026 annual meeting of stockholders (the “Annual Meeting”) of Firefly Neuroscience, Inc., a Delaware corporation (the “Company”), the Company’s stockholders approved Amendment No. 2 to the Firefly Neuroscience, Inc.…

Filed Aug 7, 2026Accepted Aug 7, 2026, 4:30 PM EDTCIK 803578Accession 0001213900-26-086720
Share

Company context

Current securities

Historical securities (2)

Recent company filings

  1. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsSep 14, 2026
  2. 10-Q filingAug 11, 2026
  3. DEF 14A filingJul 9, 2026
  4. 424B3 filingJul 2, 2026
  5. EFFECT filingJun 30, 2026

Registered securities in this filing

FIREFLY NEUROSCIENCE, INC. · 8-K · Filed 2026-08-07

As filed in this accession. Current/historical status below comes from the governed listing record; the cover itself remains exact to this filing.

Common Stock, par value $0.0001 per share

Symbol
AIFF
Exchange
NASDAQ
Classification
COMMON
Status
Current
Filing context

Context: AsOf2026-08-05

Dimensions: Not supplied

Accession 000121390026086720 · 1 registered-security cover member

Read the exact SEC filing ↗

Disclosure sections

Items 5.02, 5.03, 5.07, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 5, 2026, at the 2026 annual meeting of stockholders (the “Annual Meeting”) of Firefly Neuroscience, Inc., a Delaware corporation (the “Company”), the Company’s stockholders approved Amendment No. 2 to the Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan (the “Plan Amendment”), which amended the Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan (as amended, the “Plan”). The approval of the Plan Amendment increased the maximum number of shares available for grant under the Plan (the “Plan Share Limit”) by 2,000,000 shares of common stock, par value $0.0001 per share (the “Common Stock”), and updated the Plan’s evergreen provision. A description of the Plan is set forth in the Company’s Definitive Proxy Statement on Schedule 14A, as filed with the Securities and Exchange Commission (the “SEC”) on July 9, 2026 (the “Proxy Statement”), the relevant portions of which are incorporated by reference herein. A copy of the Plan Amendment is filed as Exhibit 10.1 to this Current Report on Form 8-K, and the description above is qualified in its entirety by reference to the full text of such exhibit.
Item 5.03Item 5.03 - Amendments to Articles/Bylaws
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. Amendment No. 2 of Amended and Restated Certificate of Incorporation, As Amended In connection with the approval by the stockholders of the Company at the Annual Meeting of a proposal to amend the Amended and Restated Certificate of Incorporation of the Company, as amended, to decrease the total number of authorized shares from 5,001,000,000 to 101,000,000, consisting of (i) 100,000,000 shares of Common Stock, and (ii) 1,000,000 shares of preferred stock, par value $0.0001 per share (the “Preferred Stock”) (the “Charter Amendment Authorization”), on August 5, 2026, the Company filed the Amendment No. 2 of Amended and Restated Certificate of Incorporation, As Amended (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware, which became effective on August 5, 2026, to effect the Charter Amendment Authorization. The foregoing description of the Certificate of Amendment is a summary only and is qualified in its entirety by reference to the complete text of the Certificate of Amendment, a copy of which is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated by reference herein. Additional information regarding the submission and approval of the proposal relating to the Charter Amendment Authorization is disclosed under Item 5.07 below.
Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders. On August 5, 2026, the Company held the Annual Meeting. As of June 8, 2026, the record date for the Annual Meeting, there were 15,604,571 shares of common stock, issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 9,703,536 shares were present in person or represented by proxy, which constituted a quorum. The holders of shares of the common stock are entitled to one vote for each share held. At the Annual Meeting, the stockholders voted on six proposals, each of which is described in greater detail in the Proxy Statement, the relevant portions of which are incorporated by reference herein. At the Annual Meeting, stockholders approved Proposals 1, 2, 3, 4, 5 and 6, each of which was presented for a vote. Set forth below are the final voting results for each of the proposals submitted to a vote of the Company’s stockholders at the Annual Meeting. Proposal 1: A proposal to elect Arun Menawat as the Class III director to the Board of Directors (the “Board”) to serve until the annual meeting of stockholders to be held in 2029, or until his successor has been duly elected and qualified. The proposal was approved as set forth below: Nominee For Withheld Broker Non-Votes ───────────────────────────────────────────────────────────────────────────────────────────────── Arun Menawat 4,324,584 106,395 5,272,557 Proposal 2: A proposal to ratify the appointment of CBIZ Canada, LLP (formerly known as Marcum Canada, LLP) as the Company’s independent registered public accounting firm for the Company’s fiscal year ending December 31, 2026. The proposal was approved as set forth below: For Against Abstain ──────────────────────────────────────────────────────────────── 9,500,723 21,341 181,472 Proposal 3: A proposal to approve, on a non-binding, advisory basis, the compensation paid to our named executive officers. The proposal was approved as set forth below: For Against Abstain Broker Non-Votes ──────────────────────────────────────────────────────────────────────────────────────────────────── 4,331,361 76,601 23,017 5,272,557 Proposal 4: A proposal to approve Amendment No. 2 to the Firefly Neuroscience, Inc. 2024 Long-Term Incentive Plan, as amended, to increase the maximum number of shares available for grant under the Plan by 2,000,000 shares of common stock and update the Plan’s evergreen provision. The proposal was approved as set forth below: For Against Abstain Broker Non-Votes ───────────────────────────────────────────────────────────────────────────────────────────────────── 4,047,217 361,601 22,161 5,272,557 Proposal 5: A proposal to approve Certificate of Amendment No. 2 of Amended and Restated Certificate of Incorporation of Firefly Neuroscience, Inc., as amended, to decrease the total number of authorized shares from 5,001,000,000 to 101,000,000, consisting of (i) 100,000,000 shares of Common Stock, and (ii) 1,000,000 shares of Preferred Stock. The proposal was approved as set forth below: For Against Abstain ───────────────────────────────────────────────────────────────── 9,222,775 268,441 212,320 Proposal 6: A proposal to approve the adjournment of the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of any one or more of the foregoing proposals. The proposal was approved as set forth below: For Against Abstain ───────────────────────────────────────────────────────────────── 9,117,363 387,451 198,722

Privacy choices

BCS measures page use with Google Analytics using regional consent settings. You can change your preference here. Charts and market data remain available.

Essential functions — always available. Security, navigation, registration and remembering these choices.

Audience analytics

Analytics cookies are off by default for visitors Google identifies in the EEA, UK or Switzerland until allowed. Limited measurement without analytics cookies may still occur under those regional defaults.

TradingView charts, quotes and the economic calendar load automatically as page content. TradingView receives network and browser information and may collect its own usage analytics. This choice controls BCS’s Google Analytics only.

Google advertising is not enabled. Direct sponsor links do not load advertising trackers on BCS.

Turning analytics off stops future Google Analytics activity here. It does not erase information already received by the provider. Read the privacy policy.